SCHEMBL775627

SCHEMBL775627

CC(SSC(C)c1ccccc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TAAR1 Q96RJ0 4/20 0.44
CYP2D6 P10635 2/20 0.42
ADRA2A P08913 1/20 0.42
ADRA2C P18825 1/20 0.42
LMNA P02545 1/20 0.42
HIF1A Q16665 1/20 0.42
KDM4E B2RXH2 1/20 0.42
DPP4 P27487 2/20 0.41
TSHR P16473 2/20 0.41
F2 P00734 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HRH1 P35367 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
SLC6A4 P31645 1/20 0.39
CYP2C19 P33261 1/20 0.39
SLC6A3 Q01959 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4266708 0.89 KMT2A (0.42) KMT2AL3MBTL1TAAR1CYP2D6ADRA2A
SCHEMBL15235441 0.87 KMT2A (0.41) KMT2AL3MBTL1TAAR1CYP2D6ADRA2A
SCHEMBL9957227 0.83 MAPT (0.48) KMT2AL3MBTL1TAAR1CYP2D6ADRA2A
SCHEMBL577805 0.82 ALDH1A1 (0.46) KMT2AL3MBTL1TAAR1CYP2D6ADRA2A
SCHEMBL20809867 0.80 KMT2A (0.44) KMT2AL3MBTL1TAAR1CYP2D6ADRA2A
SCHEMBL1145689 0.80 KMT2A (0.44) KMT2AL3MBTL1TAAR1CYP2D6ADRA2A
SCHEMBL14535430 0.80 KMT2A (0.44) KMT2AL3MBTL1TAAR1CYP2D6ADRA2A
SCHEMBL24302355 0.78 ADRA2C (0.44) KMT2AL3MBTL1TAAR1CYP2D6ADRA2A
SCHEMBL22115704 0.78 TAAR1 (0.46) KMT2AL3MBTL1TAAR1CYP2D6ADRA2A
SCHEMBL12426572 0.78 KMT2A (0.42) KMT2AL3MBTL1TAAR1CYP2D6ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116272906-A Super cross-linked polymer adsorption material containing paired mercapto and preparation method thereof 哈尔滨工程大学 2023-06-23 CN claimed
CN-113265155-A Asphalt tackifier and preparation method thereof 山东鑫中和新材料科技有限公司 2021-08-17 CN claimed
CN-113122058-A Preparation method of ink and quantum dot film TCL集团股份有限公司 2021-07-16 CN claimed
US-20030176512-A1 Asymmetric disulfides and methods of using same PROLX PHARMACEUTICALS CORPORATION (CA) 2003-09-18 US claimed
CN-120001297-A Capsule 宝洁公司 2025-05-16 CN disclosed
CN-113660926-B capsule 宝洁公司 2025-03-07 CN disclosed
CN-114007734-B Method for preparing capsules 宝洁公司 2025-01-17 CN disclosed
CN-116272906-B Super cross-linked polymer adsorption material containing paired mercapto and preparation method thereof 哈尔滨工程大学 2024-12-20 CN disclosed
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 US disclosed
US-11813596-B2 Photocatalytic system and applications thereof Max Planck Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-11-14 US disclosed
US-11813596-B2 Photocatalytic system and applications thereof Max Planck Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-11-14 US disclosed
CN-114478326-B Synthesis method of saflufenacil key intermediate 安徽宁亿泰科技有限公司 2023-10-03 CN disclosed
EP-1786477-A2 METHOD OF PRESELECTION PATIENTS FOR ANTI-VEGF, ANTI-HIF-1 OR ANTI-THIOREDOXIN THERAPY Prolx Pharmaceuticals Corp. (US) 2007-05-23 EP disclosed
US-20060104902-A1 Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-05-18 US disclosed
WO-2006023658-A2 METHOD OF PRE-SELECTING PATIENTS FOR ANTI-VEGF, ANTI-HIF-1 OR ANTI-THIOREDOXIN THERAPY PROLX PHARMACEUTICALS CORP. (US) 2006-03-02 WO disclosed
WO-2005007108-A2 ASYMMETRIC DISULFIDES AND METHODS OF USING SAME PROLX PHARMACEUTICALS, INC. (US) 2005-01-27 WO disclosed
US-20040116496-A1 Asymmetric Disulfides and methods of using same PROLX PHARMACEUTICALS CORP. 2004-06-17 US disclosed
US-20030176512-A1 Asymmetric disulfides and methods of using same PROLX PHARMACEUTICALS CORPORATION (CA) 2003-09-18 US disclosed
US-6552060-B1 Inhibits abnormal cellular proliferation and restores or prevents inhibition of cellular apoptosis PROLX PHARMACEUTICALS, INC. 2003-04-22 US disclosed
EP-1008296-A1 Alkoxy disulfides as antimicrobial agents ROHM AND HAAS COMPANY (US) 2000-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060104902-A1 Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy HIF1A, TXNRD3, HIF1AN KMT2A 2078/4885L3MBTL1 3506/4885TAAR1 2734/4885
US-11813596-B2 Photocatalytic system and applications thereof HCCS, CRY1, PCBP1 KMT2A 1481/4885L3MBTL1 4750/4885TAAR1 1257/4885
US-20030176512-A1 Asymmetric disulfides and methods of using same PRDX3, PDIA5, PRDX5 KMT2A 4152/4885L3MBTL1 1185/4885TAAR1 4857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.